Irinotecan/capecitabine (XELIRI) plus bevacizumab versus irinotecan/fluorouracil/leucovorin (FOLFIRI) plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: A randomized phase III trial of the Hellenic Cooperative Oncology Group (HeCOG).

被引：0
|
作者：
Pectasides, D. G.
Xanthakis, I.
Makatsoris, T.
Samantas, E.
Varthalitis, I.
Papaxoinis, G.
Papakotoulas, P.
Boumakis, E.
Papandreou, C.
Fountzilas, G.
机构：
[1] Hellen Cooperat Oncol Grp Data Off, Athens, Greece
[2] Univ Hosp Patras, Clin Oncol Lab, Patras, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3541
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3541
引用
收藏
页数：1
相关论文
共 50 条
  • [1] XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
    Pectasides, Dimitrios
    Papaxoinis, George
    Kalogeras, Konstantine T.
    Eleftheraki, Anastasia G.
    Xanthakis, Ioannis
    Makatsoris, Thomas
    Samantas, Epaminondas
    Varthalitis, Ioannis
    Papakostas, Pavlos
    Nikitas, Nikitas
    Papandreou, Christos N.
    Pentheroudakis, George
    Timotheadou, Eleni
    Koutras, Angelos
    Sgouros, Joseph
    Bafaloukos, Dimitrios
    Klouvas, George
    Economopoulos, Theofanis
    Syrigos, Konstantinos N.
    Fountzilas, George
    [J]. BMC CANCER, 2012, 12
  • [2] XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
    Dimitrios Pectasides
    George Papaxoinis
    Konstantine T Kalogeras
    Anastasia G Eleftheraki
    Ioannis Xanthakis
    Thomas Makatsoris
    Epaminondas Samantas
    Ioannis Varthalitis
    Pavlos Papakostas
    Nikitas Nikitas
    Christos N Papandreou
    George Pentheroudakis
    Eleni Timotheadou
    Angelos Koutras
    Joseph Sgouros
    Dimitrios Bafaloukos
    George Klouvas
    Theofanis Economopoulos
    Konstantinos N Syrigos
    George Fountzilas
    [J]. BMC Cancer, 12
  • [3] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer
    Kopetz, S.
    Glover, K. Y.
    Eng, C.
    Wolff, R. A.
    Chang, D. Z.
    Adinin, R. B.
    Morris, J.
    Abbruzzese, J. L.
    Hoff, P. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Hurwitz, H
    Fehrenbacher, L
    Novotny, W
    Cartwright, T
    Hainsworth, J
    Heim, W
    Berlin, J
    Baron, A
    Griffing, S
    Holmgren, E
    Ferrara, N
    Fyfe, G
    Rogers, B
    Ross, R
    Kabbinavar, F
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23): : 2335 - 2342
  • [5] CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5 fluorouracil, irinotecan) plus bevacizumab for the treatment of patients with metastatic colorectal cancer (mCRC): Interim analysis for safety of a randomized phase III trial
    Ziras, N.
    Polyzos, A.
    Kakolyris, S.
    Xenidis, N.
    Kentepozidis, N.
    Athanasiadis, A.
    Stergiou, I.
    Androulakis, N.
    Vamvakas, L.
    Souglakos, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ahmet, Bilici
    Uygun, Kazim
    Kaya, Serap
    Ustaalioglu, Bala Basak Oven
    Yildiz, Ramazan
    Temiz, Suleyman
    Seker, Mesut
    Aksu, Gorkem
    Cabuk, Devrim
    Gumus, Mahmut
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 98 - 99
  • [7] Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
    Souglakos, J.
    Ziras, N.
    Kakolyris, S.
    Boukovinas, I.
    Kentepozidis, N.
    Makrantonakis, P.
    Xynogalos, S.
    Christophyllakis, C. H.
    Kouroussis, C. H.
    Vamvakas, L.
    Georgoulias, V.
    Polyzos, A.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (03) : 453 - 459
  • [8] Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
    J Souglakos
    N Ziras
    S Kakolyris
    I Boukovinas
    N Kentepozidis
    P Makrantonakis
    S Xynogalos
    Ch Christophyllakis
    Ch Kouroussis
    L Vamvakas
    V Georgoulias
    A Polyzos
    [J]. British Journal of Cancer, 2012, 106 : 453 - 459
  • [9] A randomized Phase II study of tegafur/uracil (UFT), oral Leucovorin and irinotecan, combination therapy (TEGAFIRI) plus bevacizumab versus FOLFIRI plus bevacizumab for the first-line treatment of patients with metastatic colorectal cancer
    Hasegawa, H.
    Endo, T.
    Ochiai, D.
    Uchida, H.
    Okabayashi, T.
    Imai, S.
    Ishii, Y.
    Tsuruta, M.
    Kitagawa, Y.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S557 - S557
  • [10] Sequential first-line treatment for metastatic colorectal cancer with capecitabine, irinotecan, and bevacizumab: Capecitabine plus bevacizumab (Cape-Bev) versus capecitabine, irinotecan plus bevacizumab (CAPIRI-Bev): The AIO KRK 0110/ML22011 randomized, phase III trial
    Giessen, Clemens Albrecht
    Modest, Dominik Paul
    Stintzing, Sebastian
    von Weikersthal, Ludwig Fischer
    Vehling-Kaiser, Ursula
    Spaeth-Schwalbe, Ernst
    Freiberg-Richter, Jens
    Mayerle, Julia
    Bangerter, Markus
    Denzlinger, Claudio
    Sieber, Markus
    Teschendorf, Christian
    Peuser, Bettina
    Heinemann, Volker
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345